ArticleClinical ophthalmology (Auckland, N.Z.)2012
Resolution of persistent corneal erosion after administration of topical rebamipide.
Article in Clinical ophthalmology (Auckland, N.Z.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Copolymerized Polymers Based on Cyclodextrins and Cationic Groups Enhance Therapeutic Effect of Rebamipide in the N-Acetylcysteine-Treated Dry Eye Model.Drug design, development and therapy · 2024Article
- Transmembrane Mucin 1 Blocks Fluorescein Ingress to Corneal Epithelium.Investigative ophthalmology & visual science · 2022Article
- Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes.International medical case reports journal · 2016Article
- Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.Optometry and vision science : official publication of the American Academy of Optometry · 2015Article
- Histological observation of goblet cells following topical rebamipide treatment of the human ocular surface: A case report.Experimental and therapeutic medicine · 2015Article
- Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Topical rebamipide improves the ocular surface in mild lagophthalmos.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Topical rebamipide improves lid wiper epitheliopathy.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Alkali burn treated with 2% rebamipide ophthalmic suspension: a case report.Case reports in ophthalmologyArticle
- Diabetic keratopathy: Insights and challenges.Survey of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rebamipide is an antiulcer agent used to treat gastric ulcer and gastritis. Biological effects of rebamipide include cytoprotection, wound healing, and anti-inflammatory properties that are known to be universal for a variety of tissues in addition to gastrointestinal mucosa. The therapeutic effects of rebamipide eye drops are due to its ability to increase corneal and conjunctival mucin-like substances and improve corneal and conjunctival injury in vivo. In this paper, we report a case of Sjögren's syndrome with complete disappearance of corneal erosion after administration of rebamipide eye drops. This was observed even though corneal erosion had not improved for 6 months after punctal occlusion surgery. The patient was a 33-year-old female, diagnosed with Sjögren's syndrome by a salivary gland biopsy. The corneal and conjunctival surfaces were filled with dense erosions, which did not improve with topical drugs. Punctal plugs were applied several times; however, the plugs were repeatedly shed. All four puncta of both eyelids were surgically occluded, and both corneal and conjunctival erosion was clearly improved. However, the erosion in the inferior cornea of both eyes had not improved for 6 months after surgery. We used the newly approved topical rebamipide for treatment of this patient. The corneal erosion gradually improved and completely disappeared 4 weeks after administration of the drug. Dry eye sensation disappeared at the same time. Both membrane-associated mucin and secreted mucin in the ocular surface are thought to be essential for maintenance of the tear film. Induction of mucin from ocular surface epithelium could be an effective treatment in cases of dry eye caused by mucin deficiency. Through its various mechanisms, rebamipide improves ocular surface conditions. To our knowledge, this is the first clinical case report using rebamipide ophthalmic solution. This drug may provide a novel approach to treat drying diseases of the eye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.